HVNI与NIPPV治疗急性失代偿性心力衰竭:急诊多中心试验的亚组分析
该亚组分析来自一项纳入急诊呼吸衰竭需NIPPV支持成人的大型随机对照试验,按出院诊断ADHF筛选出22例HVNI和20例NIPPV患者,主要终点为入组后72小时治疗失败(需插管或包括主观交叉到替代治疗的全因组失败)。插管率(p=1.000)和治疗成功率(p=1.000)均无统计学显著差异,初始4小时生命体征、呼吸困难及血气变化可比。医生对HVNI的患者舒适度/耐受性(p<0.001)、易用性(p=0.004)和监测(p=0.036)评分更优。作者认为HVNI在无需紧急插管的ADHF所致呼吸衰竭患者中可能不劣于NIPPV,但亚组把握度不足且无法对临床团队设盲。
要点
- 在因ADHF导致呼吸衰竭且无需紧急插管的急诊成人中,HVNI组与NIPPV组72小时插管率无统计学显著差异(p=1.000)。
- HVNI组与NIPPV组72小时治疗成功率无统计学显著差异(p=1.000),治疗失败定义包括需插管或全因组失败(含主观交叉到替代治疗)。
- 初始4小时重复测量的生命体征、呼吸困难和血气变化在两组间具有可比性。
- 医生对HVNI的患者舒适度/耐受性(p<0.001)、易用性(p=0.004)和监测(p=0.036)评分优于NIPPV。
适用人群与场景
- 来自一项大型随机对照试验的成人急诊患者,因呼吸衰竭需要NIPPV支持。
- 亚组按出院诊断急性失代偿性心力衰竭(ADHF)筛选,纳入22例HVNI和20例NIPPV患者。
研究设计与关键结果
- 研究类型:大型随机对照试验的亚组分析;样本量:HVNI组22例,NIPPV组20例;人群:急诊呼吸衰竭需NIPPV支持且出院诊断为ADHF的成人;干预:HVNI对比NIPPV;主要终点:入组后72小时治疗失败(需插管或全因组失败包括主观交叉到替代治疗)。
- 主要终点结果:插管率无统计学显著差异(p=1.000);治疗成功率无统计学显著差异(p=1.000)。
- 重复测量(生命体征、呼吸困难、血气)在初始4小时内两组差异具有可比性。
- 医生评分:HVNI在患者舒适度/耐受性(p<0.001)、易用性(p=0.004)和监测(p=0.036)方面优于NIPPV。
证据类型、等级与局限
- 证据类型:随机对照试验的亚组分析。
- 局限:原文报告技术性无法对临床团队设盲;亚组分析把握度不足。
对床旁实践的改变
- 作者认为,对于因ADHF导致呼吸衰竭且不需要紧急插管的患者,HVNI可能不劣于NIPPV。
- 医生评分显示HVNI在患者舒适度/耐受性、易用性和监测方面优于NIPPV。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: Managing respiratory failure (RF) secondary to acute decompensated heart failure (ADHF) with non-invasive positive-pressure ventilation (NIPPV) has been shown to significantly improve morbidity and mortality in patients presenting to the emergency department (ED). This subgroup analysis compares high-velocity nasal insufflation (HVNI), a form of high-flow nasal cannula, with NIPPV in the treatment of RF secondary to ADHF with respect to therapy failure, as indicated by the requirement for intubation or all-cause arm failure including subjective crossover to the alternate therapy.
METHODS: The subgroup analysis is from a larger randomized control trial of adults presenting to the ED with RF requiring NIPPV support. Patients were randomly selected to therapy, and subgroup selection was established a priori in the original study as a discharge diagnosis. The primary outcome was therapy failure at 72 h after enrolment.
RESULTS: Subgroup analysis included a total of 22 HVNI and 20 NIPPV patients which fit discharge diagnosis ADHF. Baseline patient characteristics were not statistically significant. Primary outcomes were not statistically significant: intubation rate (p = 1.000), therapy success (p = 1.000). Repeated measures (vitals, dyspnea, blood gases) showed comparable differences over initial 4 h. Physicians scored HVNI superior on patient comfort/tolerance (p < 0.001), ease of use (p = 0.004), and monitoring (p = 0.036). Limitations were technical inability to blind the clinician team and lack of power of the subgroup analysis.
CONCLUSION: In conclusion, this subgroup analysis suggests HVNI may be non-inferior to NIPPV in patients with respiratory failure secondary to ADHF that do not need emergent intubation.
参考来源
- Haywood ST, Whittle JS, Volakis LI, et al. HVNI vs NIPPV in the treatment of acute decompensated heart failure: Subgroup analysis of a multi-center trial in the ED. Am J Emerg Med. 2019. PMID: 30880040. doi:10.1016/j.ajem.2019.03.002
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。